Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics' stock price has experienced significant fluctuations over the past six months. As of March 25, 2026, the share price was $13.95, a 59.79% increase from $8.73 on March 27, 2025. The 52-week high was $20.72 and the low was $3.39. Avalo reported a net loss of $78.3 million for 2025, driven by higher R&D expenses. Topline data from the Phase 2 LOTUS trial for abdakibart is expected in the second quarter of 2026. The company's cash is expected to fund operations into 2028. Analyst ratings generally lean towards a "Moderate Buy" or "Strong Buy" consensus, with an average price target of $42.25, although some analyses point to a "Strong Sell". The company has also undergone a reverse stock split.

Avalo Therapeutics, Inc. does not currently have commercialized products or services, and therefore, there is no direct demand seasonality for its products or services. Historically, June has shown the highest probability of positive returns for AVTX stock, while March may not be an ideal month for investment. This seasonality relates to investor behavior and market trends rather than product demand.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune dysregulation and immune-mediated inflammatory diseases. The company operates in the Healthcare sector, specifically in the Biotechnology & Medical Research industry. Avalo's primary focus is on developing IL-1β-based treatments, with its lead asset being AVTX-009 (abdakibart), currently in a Phase 2 clinical trial for hidradenitis suppurativa (HS).

Avalo Therapeutics, Inc. is headquartered in Rockville, Maryland, and also lists a headquarters in Wayne, Pennsylvania, United States. The company's market focus is primarily within the United States.

Avalo Therapeutics' brand reputation is primarily influenced by its clinical development progress, financial health, and analyst sentiment. Analyst ratings generally reflect a positive outlook, with a consensus of "Moderate Buy" or "Strong Buy". The company has faced challenges, including significant net losses and increased expenses due to R&D investments. The success or failure of its clinical trials will be the most significant factor in shaping its reputation going forward.

Avalo Therapeutics, Inc. has a significant institutional ownership presence. As of December 2025, there were 83 institutional filers holding a collective stake of 143.9% in Avalo Therapeutics, representing 20.12 million shares. Armistice Capital LLC is noted as the largest individual shareholder, owning 51.62 million shares, representing 226.50% of the company. Institutional shareholders hold 87.26% of the stock, while Avalo Therapeutics insiders hold 356.58%, and retail investors hold 0.00%.